GENTAUR Belgium BVBA BE0473327336 Voortstraat 49, 1910 Kampenhout BELGIUM Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc,Logistics 547 Yurok Circle, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, [email protected]

Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, Gentaur another in time delivery

Toll-like receptor 1 (Toll/interleukin-1 receptor-like protein) (TIL) (CD antigen CD281)

 TLR1_HUMAN              Reviewed;         786 AA.
Q15399; D1CS39; D1CS41; O15452; Q32MK3; Q32MK4; Q9UG90;
31-JAN-2002, integrated into UniProtKB/Swiss-Prot.
01-MAY-2007, sequence version 3.
17-JUN-2020, entry version 201.
RecName: Full=Toll-like receptor 1;
EC=3.2.2.6 {ECO:0000255|PROSITE-ProRule:PRU00204};
AltName: Full=Toll/interleukin-1 receptor-like protein;
Short=TIL;
AltName: CD_antigen=CD281;
Flags: Precursor;
Name=TLR1; Synonyms=KIAA0012;
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
Homo.
NCBI_TaxID=9606;
[1]
NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS SER-248 AND ILE-602.
TISSUE=Erythroleukemia;
PubMed=9435236; DOI=10.1073/pnas.95.2.588;
Rock F.L., Hardiman G., Timans J.C., Kastelein R.A., Bazan J.F.;
"A family of human receptors structurally related to Drosophila Toll.";
Proc. Natl. Acad. Sci. U.S.A. 95:588-593(1998).
[2]
NUCLEOTIDE SEQUENCE [MRNA].
PubMed=18810425; DOI=10.1007/s00251-008-0332-0;
Nakajima T., Ohtani H., Satta Y., Uno Y., Akari H., Ishida T., Kimura A.;
"Natural selection in the TLR-related genes in the course of primate
evolution.";
Immunogenetics 60:727-735(2008).
[3]
NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS THR-80 AND ILE-602.
PubMed=19924287; DOI=10.1371/journal.pone.0007803;
Georgel P., Macquin C., Bahram S.;
"The heterogeneous allelic repertoire of human Toll-Like receptor (TLR)
genes.";
PLoS ONE 4:E7803-E7803(2009).
[4]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT THR-80.
TISSUE=Bone marrow;
PubMed=7584026; DOI=10.1093/dnares/1.1.27;
Nomura N., Miyajima N., Sazuka T., Tanaka A., Kawarabayasi Y., Sato S.,
Nagase T., Seki N., Ishikawa K., Tabata S.;
"Prediction of the coding sequences of unidentified human genes. I. The
coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of
randomly sampled cDNA clones from human immature myeloid cell line KG-1.";
DNA Res. 1:27-35(1994).
[5]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS SER-248 AND ILE-602.
TISSUE=Brain;
PubMed=11230166; DOI=10.1101/gr.gr1547r;
Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H., Lauber J.,
Duesterhoeft A., Beyer A., Koehrer K., Strack N., Mewes H.-W.,
Ottenwaelder B., Obermaier B., Tampe J., Heubner D., Wambutt R., Korn B.,
Klein M., Poustka A.;
"Towards a catalog of human genes and proteins: sequencing and analysis of
500 novel complete protein coding human cDNAs.";
Genome Res. 11:422-435(2001).
[6]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS SER-248 AND ILE-602.
PubMed=15489334; DOI=10.1101/gr.2596504;
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA project:
the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[7]
PROTEIN SEQUENCE OF 25-39.
PubMed=15340161; DOI=10.1110/ps.04682504;
Zhang Z., Henzel W.J.;
"Signal peptide prediction based on analysis of experimentally verified
cleavage sites.";
Protein Sci. 13:2819-2824(2004).
[8]
FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH TLR2 AND CD14.
PubMed=16880211; DOI=10.1074/jbc.m602794200;
Triantafilou M., Gamper F.G., Haston R.M., Mouratis M.A., Morath S.,
Hartung T., Triantafilou K.;
"Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers
at the cell surface determines heterotypic associations with CD36 and
intracellular targeting.";
J. Biol. Chem. 281:31002-31011(2006).
[9]
INVOLVEMENT IN PROTECTION AGAINST LEPROSY.
PubMed=17548585; DOI=10.4049/jimmunol.178.12.7520;
Johnson C.M., Lyle E.A., Omueti K.O., Stepensky V.A., Yegin O., Alpsoy E.,
Hamann L., Schumann R.R., Tapping R.I.;
"Cutting edge: A common polymorphism impairs cell surface trafficking and
functional responses of TLR1 but protects against leprosy.";
J. Immunol. 178:7520-7524(2007).
[10]
GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-163.
TISSUE=Liver;
PubMed=19159218; DOI=10.1021/pr8008012;
Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
"Glycoproteomics analysis of human liver tissue by combination of multiple
enzyme digestion and hydrazide chemistry.";
J. Proteome Res. 8:651-661(2009).
[11]
FUNCTION.
TISSUE=T-cell;
PubMed=21078852; DOI=10.1128/iai.00806-10;
Lancioni C.L., Li Q., Thomas J.J., Ding X., Thiel B., Drage M.G.,
Pecora N.D., Ziady A.G., Shank S., Harding C.V., Boom W.H., Rojas R.E.;
"Mycobacterium tuberculosis lipoproteins directly regulate human memory
CD4(+) T cell activation via Toll-like receptors 1 and 2.";
Infect. Immun. 79:663-673(2011).
[12]
X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 625-785.
PubMed=11081518; DOI=10.1038/35040600;
Xu Y., Tao X., Shen B., Horng T., Medzhitov R., Manley J.L., Tong L.;
"Structural basis for signal transduction by the Toll/interleukin-1
receptor domains.";
Nature 408:111-115(2000).
[13]
X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 25-476 IN COMPLEX WITH TLR2 AND
BACTERIAL LIPOPEPTIDE ANALOG, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-51;
ASN-163; ASN-330 AND ASN-429.
PubMed=17889651; DOI=10.1016/j.cell.2007.09.008;
Jin M.S., Kim S.E., Heo J.Y., Lee M.E., Kim H.M., Paik S.-G., Lee H.,
Lee J.-O.;
"Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a
tri-acylated lipopeptide.";
Cell 130:1071-1082(2007).
[14]
ASSOCIATION OF VARIANT SER-248 WITH SUSCEPTIBILITY TO LEPROSY.
PubMed=19456232; DOI=10.1086/599121;
Schuring R.P., Hamann L., Faber W.R., Pahan D., Richardus J.H.,
Schumann R.R., Oskam L.;
"Polymorphism N248S in the human Toll-like receptor 1 gene is related to
leprosy and leprosy reactions.";
J. Infect. Dis. 199:1816-1819(2009).
[15]
VARIANTS PRO-44; THR-75; THR-80; TYR-118; SER-248; LEU-305; LEU-315;
ASN-352; VAL-460; ALA-542; CYS-554; GLY-587; ILE-602; ALA-651; ALA-674;
PRO-720 AND LEU-733, AND CHARACTERIZATION OF VARIANTS LEU-315; CYS-554;
ILE-602; ALA-651 AND PRO-720.
PubMed=21618349; DOI=10.1002/humu.21486;
Ben-Ali M., Corre B., Manry J., Barreiro L.B., Quach H., Boniotto M.,
Pellegrini S., Quintana-Murci L.;
"Functional characterization of naturally occurring genetic variants in the
human TLR1-2-6 gene family.";
Hum. Mutat. 32:643-652(2011).
-!- FUNCTION: Participates in the innate immune response to microbial
agents. Specifically recognizes diacylated and triacylated
lipopeptides. Cooperates with TLR2 to mediate the innate immune
response to bacterial lipoproteins or lipopeptides (PubMed:21078852).
Forms the activation cluster TLR2:TLR1:CD14 in response to triacylated
lipopeptides, this cluster triggers signaling from the cell surface and
subsequently is targeted to the Golgi in a lipid-raft dependent pathway
(PubMed:16880211). Acts via MYD88 and TRAF6, leading to NF-kappa-B
activation, cytokine secretion and the inflammatory response.
{ECO:0000269|PubMed:16880211, ECO:0000269|PubMed:21078852}.
-!- CATALYTIC ACTIVITY:
Reaction=H2O + NAD(+) = ADP-D-ribose + H(+) + nicotinamide;
Xref=Rhea:RHEA:16301, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
ChEBI:CHEBI:17154, ChEBI:CHEBI:57540, ChEBI:CHEBI:57967; EC=3.2.2.6;
Evidence={ECO:0000255|PROSITE-ProRule:PRU00204};
PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:16302;
Evidence={ECO:0000255|PROSITE-ProRule:PRU00204};
-!- SUBUNIT: Interacts (via extracellular domain) with TLR2. TLR2 seems to
exist in heterodimers with either TLR1 or TLR6 before stimulation by
the ligand. The heterodimers form bigger oligomers in response to their
corresponding ligands as well as further heterotypic associations with
other receptors such as CD14 and/or CD36 (PubMed:16880211,
PubMed:17889651). The activation cluster TLR2:TLR1:CD14 forms in
response to triacylated lipopeptides (PubMed:16880211). Binds MYD88
(via TIR domain). Interacts with CNPY3 (By similarity).
{ECO:0000250|UniProtKB:Q9EPQ1, ECO:0000269|PubMed:16880211,
ECO:0000269|PubMed:17889651}.
-!- INTERACTION:
Q15399; Q15399: TLR1; NbExp=3; IntAct=EBI-9009517, EBI-9009517;
Q15399; Q9BXR5: TLR10; NbExp=3; IntAct=EBI-9009517, EBI-16825459;
Q15399; O60603: TLR2; NbExp=3; IntAct=EBI-9009517, EBI-973722;
-!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16880211};
Single-pass type I membrane protein {ECO:0000255}. Cytoplasmic vesicle,
phagosome membrane {ECO:0000250|UniProtKB:Q9EPQ1}; Single-pass type I
membrane protein {ECO:0000255}. Membrane raft
{ECO:0000269|PubMed:16880211}. Golgi apparatus
{ECO:0000269|PubMed:16880211}. Note=Does not reside in lipid rafts
before stimulation but accumulates increasingly in the raft upon the
presence of the microbial ligand. In response to triacylated
lipoproteins, TLR2:TLR1 heterodimers are recruited in lipid rafts, this
recruitment determine the intracellular targeting to the Golgi
apparatus. {ECO:0000269|PubMed:16880211}.
-!- TISSUE SPECIFICITY: Ubiquitous. Highly expressed in spleen, ovary,
peripheral blood leukocytes, thymus and small intestine.
-!- DOMAIN: The TIR domain mediates NAD(+) hydrolase (NADase) activity.
Self-association of TIR domains is required for NADase activity.
{ECO:0000255|PROSITE-ProRule:PRU00204}.
-!- POLYMORPHISM: Genetic variations in TLR1 may influence susceptibility
to or protection against contracting leprosy and define the leprosy
susceptibility locus 5 [MIM:613223]. Ser-602 is a common allele in
Caucasians. It is associated with impaired cell surface expression and
receptor function resulting in protection against leprosy.
-!- SIMILARITY: Belongs to the Toll-like receptor family. {ECO:0000305}.
-!- SEQUENCE CAUTION:
Sequence=BAA02801.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
---------------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
---------------------------------------------------------------------------
EMBL; U88540; AAC34137.1; -; mRNA.
EMBL; AB445617; BAG55014.1; -; mRNA.
EMBL; DQ012259; AAY85638.1; -; mRNA.
EMBL; DQ012260; AAY85639.1; -; mRNA.
EMBL; DQ012261; AAY85640.1; -; mRNA.
EMBL; D13637; BAA02801.2; ALT_INIT; mRNA.
EMBL; AL050262; CAB43364.1; -; mRNA.
EMBL; BC109093; AAI09094.1; -; mRNA.
EMBL; BC109094; AAI09095.1; -; mRNA.
CCDS; CCDS33973.1; -.
PIR; T08664; T08664.
RefSeq; NP_003254.2; NM_003263.3.
RefSeq; XP_005262719.1; XM_005262662.4.
RefSeq; XP_011512044.1; XM_011513742.2.
RefSeq; XP_011512045.1; XM_011513743.2.
RefSeq; XP_011512046.1; XM_011513744.2.
RefSeq; XP_011512047.1; XM_011513745.2.
RefSeq; XP_016864060.1; XM_017008571.1.
RefSeq; XP_016864061.1; XM_017008572.1.
PDB; 1FYV; X-ray; 2.90 A; A=625-785.
PDB; 2Z7X; X-ray; 2.10 A; B=25-475.
PDB; 6NIH; X-ray; 2.30 A; A/B=1-475.
PDBsum; 1FYV; -.
PDBsum; 2Z7X; -.
PDBsum; 6NIH; -.
SMR; Q15399; -.
BioGRID; 112951; 13.
CORUM; Q15399; -.
IntAct; Q15399; 6.
STRING; 9606.ENSP00000354932; -.
ChEMBL; CHEMBL3885643; -.
iPTMnet; Q15399; -.
PhosphoSitePlus; Q15399; -.
BioMuta; TLR1; -.
DMDM; 146291086; -.
EPD; Q15399; -.
jPOST; Q15399; -.
MassIVE; Q15399; -.
PaxDb; Q15399; -.
PeptideAtlas; Q15399; -.
PRIDE; Q15399; -.
ProteomicsDB; 60569; -.
Antibodypedia; 10459; 642 antibodies.
Ensembl; ENST00000308979; ENSP00000354932; ENSG00000174125.
Ensembl; ENST00000502213; ENSP00000421259; ENSG00000174125.
GeneID; 7096; -.
KEGG; hsa:7096; -.
UCSC; uc003gtl.4; human.
CTD; 7096; -.
DisGeNET; 7096; -.
EuPathDB; HostDB:ENSG00000174125.7; -.
GeneCards; TLR1; -.
HGNC; HGNC:11847; TLR1.
HPA; ENSG00000174125; Tissue enhanced (blood, lymphoid tissue).
MalaCards; TLR1; -.
MIM; 601194; gene.
MIM; 613223; phenotype.
neXtProt; NX_Q15399; -.
OpenTargets; ENSG00000174125; -.
PharmGKB; PA36549; -.
eggNOG; KOG4641; Eukaryota.
eggNOG; COG4886; LUCA.
GeneTree; ENSGT00940000162884; -.
HOGENOM; CLU_006000_3_0_1; -.
InParanoid; Q15399; -.
KO; K05398; -.
OMA; NNIETTW; -.
OrthoDB; 282372at2759; -.
PhylomeDB; Q15399; -.
TreeFam; TF351113; -.
Reactome; R-HSA-1236974; ER-Phagosome pathway.
Reactome; R-HSA-1461957; Beta defensins.
Reactome; R-HSA-166058; MyD88:MAL(TIRAP) cascade initiated on plasma membrane.
Reactome; R-HSA-168179; Toll Like Receptor TLR1:TLR2 Cascade.
Reactome; R-HSA-5602498; MyD88 deficiency (TLR2/4).
Reactome; R-HSA-5603041; IRAK4 deficiency (TLR2/4).
Reactome; R-HSA-5686938; Regulation of TLR by endogenous ligand.
BioGRID-ORCS; 7096; 1 hit in 787 CRISPR screens.
EvolutionaryTrace; Q15399; -.
GeneWiki; TLR_1; -.
GenomeRNAi; 7096; -.
Pharos; Q15399; Tbio.
PRO; PR:Q15399; -.
Proteomes; UP000005640; Chromosome 4.
RNAct; Q15399; protein.
Bgee; ENSG00000174125; Expressed in leukocyte and 151 other tissues.
ExpressionAtlas; Q15399; baseline and differential.
Genevisible; Q15399; HS.
GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
GO; GO:0016020; C:membrane; NAS:UniProtKB.
GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
GO; GO:0030670; C:phagocytic vesicle membrane; IEA:UniProtKB-SubCell.
GO; GO:0005886; C:plasma membrane; TAS:Reactome.
GO; GO:0035354; C:Toll-like receptor 1-Toll-like receptor 2 protein complex; IDA:MGI.
GO; GO:0042802; F:identical protein binding; IPI:IntAct.
GO; GO:0071723; F:lipopeptide binding; IBA:GO_Central.
GO; GO:0050135; F:NAD(P)+ nucleosidase activity; IEA:UniProtKB-EC.
GO; GO:0061809; F:NAD+ nucleotidase, cyclic ADP-ribose generating; IEA:UniProtKB-EC.
GO; GO:0038023; F:signaling receptor activity; IBA:GO_Central.
GO; GO:0035663; F:Toll-like receptor 2 binding; IPI:UniProtKB.
GO; GO:0004888; F:transmembrane signaling receptor activity; NAS:UniProtKB.
GO; GO:0001775; P:cell activation; IDA:AgBase.
GO; GO:0071221; P:cellular response to bacterial lipopeptide; IBA:GO_Central.
GO; GO:0071727; P:cellular response to triacyl bacterial lipopeptide; IDA:UniProtKB.
GO; GO:0042495; P:detection of triacyl bacterial lipopeptide; IDA:MGI.
GO; GO:0006955; P:immune response; TAS:ProtInc.
GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
GO; GO:0042116; P:macrophage activation; NAS:UniProtKB.
GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:Reactome.
GO; GO:0045410; P:positive regulation of interleukin-6 biosynthetic process; ISS:UniProtKB.
GO; GO:2000484; P:positive regulation of interleukin-8 secretion; IGI:ARUK-UCL.
GO; GO:0034137; P:positive regulation of toll-like receptor 2 signaling pathway; IGI:ARUK-UCL.
GO; GO:0042535; P:positive regulation of tumor necrosis factor biosynthetic process; ISS:UniProtKB.
GO; GO:0007165; P:signal transduction; TAS:ProtInc.
GO; GO:0034130; P:toll-like receptor 1 signaling pathway; IEA:InterPro.
GO; GO:0002224; P:toll-like receptor signaling pathway; IBA:GO_Central.
GO; GO:0038123; P:toll-like receptor TLR1:TLR2 signaling pathway; TAS:Reactome.
Gene3D; 3.40.50.10140; -; 1.
Gene3D; 3.80.10.10; -; 1.
InterPro; IPR000483; Cys-rich_flank_reg_C.
InterPro; IPR001611; Leu-rich_rpt.
InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
InterPro; IPR032675; LRR_dom_sf.
InterPro; IPR000157; TIR_dom.
InterPro; IPR027190; TLR1.
InterPro; IPR035897; Toll_tir_struct_dom_sf.
PANTHER; PTHR24365:SF261; PTHR24365:SF261; 1.
Pfam; PF13855; LRR_8; 2.
Pfam; PF01463; LRRCT; 1.
Pfam; PF01582; TIR; 1.
SMART; SM00369; LRR_TYP; 4.
SMART; SM00082; LRRCT; 1.
SMART; SM00255; TIR; 1.
SUPFAM; SSF52200; SSF52200; 1.
PROSITE; PS51450; LRR; 10.
PROSITE; PS50104; TIR; 1.
1: Evidence at protein level;
3D-structure; Cell membrane; Cytoplasmic vesicle;
Direct protein sequencing; Disulfide bond; Glycoprotein; Golgi apparatus;
Hydrolase; Immunity; Inflammatory response; Innate immunity;
Leucine-rich repeat; Membrane; NAD; Polymorphism; Receptor;
Reference proteome; Repeat; Signal; Transmembrane; Transmembrane helix.
SIGNAL 1..24
/evidence="ECO:0000269|PubMed:15340161"
CHAIN 25..786
/note="Toll-like receptor 1"
/id="PRO_0000034705"
TOPO_DOM 25..580
/note="Extracellular"
/evidence="ECO:0000255"
TRANSMEM 581..601
/note="Helical"
/evidence="ECO:0000255"
TOPO_DOM 602..786
/note="Cytoplasmic"
/evidence="ECO:0000255"
REPEAT 54..77
/note="LRR 1"
REPEAT 78..101
/note="LRR 2"
REPEAT 102..125
/note="LRR 3"
REPEAT 126..150
/note="LRR 4"
REPEAT 151..175
/note="LRR 5"
REPEAT 176..199
/note="LRR 6"
REPEAT 200..223
/note="LRR 7"
REPEAT 224..250
/note="LRR 8"
REPEAT 251..278
/note="LRR 9"
REPEAT 279..308
/note="LRR 10"
REPEAT 309..337
/note="LRR 11"
REPEAT 338..361
/note="LRR 12"
REPEAT 362..388
/note="LRR 13"
REPEAT 389..414
/note="LRR 14"
REPEAT 415..437
/note="LRR 15"
REPEAT 438..457
/note="LRR 16"
REPEAT 458..478
/note="LRR 17"
REPEAT 479..500
/note="LRR 18"
REPEAT 501..524
/note="LRR 19"
DOMAIN 525..579
/note="LRRCT"
DOMAIN 635..776
/note="TIR"
/evidence="ECO:0000255|PROSITE-ProRule:PRU00204"
REGION 313..316
/note="Interaction with bacterial lipopeptide"
ACT_SITE 710
/evidence="ECO:0000255|PROSITE-ProRule:PRU00204"
CARBOHYD 51
/note="N-linked (GlcNAc...) asparagine"
/evidence="ECO:0000269|PubMed:17889651"
CARBOHYD 137
/note="N-linked (GlcNAc...) asparagine"
/evidence="ECO:0000255"
CARBOHYD 163
/note="N-linked (GlcNAc...) asparagine"
/evidence="ECO:0000269|PubMed:17889651,
ECO:0000269|PubMed:19159218"
CARBOHYD 330
/note="N-linked (GlcNAc...) asparagine"
/evidence="ECO:0000269|PubMed:17889651"
CARBOHYD 429
/note="N-linked (GlcNAc...) asparagine"
/evidence="ECO:0000269|PubMed:17889651"
CARBOHYD 578
/note="N-linked (GlcNAc...) asparagine"
/evidence="ECO:0000255"
DISULFID 110..132
/evidence="ECO:0000269|PubMed:17889651"
DISULFID 223..230
/evidence="ECO:0000269|PubMed:17889651"
DISULFID 343..368
/evidence="ECO:0000269|PubMed:17889651"
DISULFID 419..442
/evidence="ECO:0000269|PubMed:17889651"
VARIANT 44
/note="S -> P (in dbSNP:rs76600635)"
/evidence="ECO:0000269|PubMed:21618349"
/id="VAR_066340"
VARIANT 75
/note="I -> T (in dbSNP:rs137853170)"
/evidence="ECO:0000269|PubMed:21618349"
/id="VAR_066341"
VARIANT 80
/note="R -> T (in dbSNP:rs5743611)"
/evidence="ECO:0000269|PubMed:19924287,
ECO:0000269|PubMed:21618349, ECO:0000269|PubMed:7584026"
/id="VAR_031916"
VARIANT 118
/note="H -> Y (in dbSNP:rs5743612)"
/evidence="ECO:0000269|PubMed:21618349"
/id="VAR_018474"
VARIANT 248
/note="N -> S (may confer susceptibility to leprosy;
dbSNP:rs4833095)"
/evidence="ECO:0000269|PubMed:11230166,
ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:21618349,
ECO:0000269|PubMed:9435236"
/id="VAR_031917"
VARIANT 305
/note="H -> L (in dbSNP:rs3923647)"
/evidence="ECO:0000269|PubMed:21618349"
/id="VAR_031918"
VARIANT 315
/note="P -> L (severe impairment of activity;
dbSNP:rs5743613)"
/evidence="ECO:0000269|PubMed:21618349"
/id="VAR_031919"
VARIANT 352
/note="H -> N (in dbSNP:rs76796448)"
/evidence="ECO:0000269|PubMed:21618349"
/id="VAR_066342"
VARIANT 460
/note="I -> V (in dbSNP:rs137853171)"
/evidence="ECO:0000269|PubMed:21618349"
/id="VAR_066343"
VARIANT 542
/note="V -> A (in dbSNP:rs137853172)"
/evidence="ECO:0000269|PubMed:21618349"
/id="VAR_066344"
VARIANT 554
/note="Y -> C (severe impairment of activity;
dbSNP:rs137853173)"
/evidence="ECO:0000269|PubMed:21618349"
/id="VAR_066345"
VARIANT 587
/note="V -> G (in dbSNP:rs5743617)"
/evidence="ECO:0000269|PubMed:21618349"
/id="VAR_031920"
VARIANT 602
/note="S -> I (severe impairment of activity;
dbSNP:rs5743618)"
/evidence="ECO:0000269|PubMed:11230166,
ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:19924287,
ECO:0000269|PubMed:21618349, ECO:0000269|PubMed:9435236"
/id="VAR_031921"
VARIANT 631
/note="L -> R (in dbSNP:rs5743619)"
/id="VAR_052358"
VARIANT 651
/note="V -> A (severe impairment of activity;
dbSNP:rs137853174)"
/evidence="ECO:0000269|PubMed:21618349"
/id="VAR_066346"
VARIANT 674
/note="V -> A"
/evidence="ECO:0000269|PubMed:21618349"
/id="VAR_066347"
VARIANT 720
/note="H -> P (severe impairment of activity;
dbSNP:rs113706342)"
/evidence="ECO:0000269|PubMed:21618349"
/id="VAR_066348"
VARIANT 733
/note="P -> L (in dbSNP:rs5743621)"
/evidence="ECO:0000269|PubMed:21618349"
/id="VAR_052359"
CONFLICT 182
/note="E -> G (in Ref. 5; CAB43364)"
/evidence="ECO:0000305"
CONFLICT 228
/note="N -> S (in Ref. 5; CAB43364)"
/evidence="ECO:0000305"
CONFLICT 276
/note="F -> S (in Ref. 5; CAB43364)"
/evidence="ECO:0000305"
STRAND 28..30
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 48..51
/evidence="ECO:0000244|PDB:2Z7X"
HELIX 62..65
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 73..75
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 83..85
/evidence="ECO:0000244|PDB:2Z7X"
HELIX 86..89
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 97..99
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 107..109
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 117..120
/evidence="ECO:0000244|PDB:2Z7X"
HELIX 133..137
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 143..150
/evidence="ECO:0000244|PDB:2Z7X"
HELIX 153..159
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 164..171
/evidence="ECO:0000244|PDB:2Z7X"
TURN 173..178
/evidence="ECO:0000244|PDB:6NIH"
HELIX 181..184
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 189..195
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 198..200
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 214..218
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 221..223
/evidence="ECO:0000244|PDB:2Z7X"
TURN 227..230
/evidence="ECO:0000244|PDB:2Z7X"
HELIX 231..238
/evidence="ECO:0000244|PDB:2Z7X"
HELIX 239..242
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 248..257
/evidence="ECO:0000244|PDB:2Z7X"
HELIX 258..269
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 274..285
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 301..309
/evidence="ECO:0000244|PDB:2Z7X"
HELIX 317..324
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 329..336
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 352..354
/evidence="ECO:0000244|PDB:2Z7X"
TURN 362..367
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 376..378
/evidence="ECO:0000244|PDB:2Z7X"
HELIX 387..394
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 402..404
/evidence="ECO:0000244|PDB:2Z7X"
HELIX 414..416
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 427..429
/evidence="ECO:0000244|PDB:2Z7X"
HELIX 437..441
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 449..451
/evidence="ECO:0000244|PDB:2Z7X"
HELIX 462..466
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 472..474
/evidence="ECO:0000244|PDB:2Z7X"
TURN 487..491
/evidence="ECO:0000244|PDB:2Z7X"
HELIX 504..516
/evidence="ECO:0000244|PDB:2Z7X"
TURN 517..520
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 521..523
/evidence="ECO:0000244|PDB:2Z7X"
TURN 529..531
/evidence="ECO:0000244|PDB:2Z7X"
HELIX 536..538
/evidence="ECO:0000244|PDB:2Z7X"
STRAND 631..633
/evidence="ECO:0000244|PDB:1FYV"
STRAND 637..642
/evidence="ECO:0000244|PDB:1FYV"
HELIX 645..647
/evidence="ECO:0000244|PDB:1FYV"
HELIX 648..653
/evidence="ECO:0000244|PDB:1FYV"
HELIX 655..660
/evidence="ECO:0000244|PDB:1FYV"
TURN 661..663
/evidence="ECO:0000244|PDB:1FYV"
TURN 669..672
/evidence="ECO:0000244|PDB:1FYV"
HELIX 679..689
/evidence="ECO:0000244|PDB:1FYV"
STRAND 690..698
/evidence="ECO:0000244|PDB:1FYV"
HELIX 699..704
/evidence="ECO:0000244|PDB:1FYV"
HELIX 707..712
/evidence="ECO:0000244|PDB:1FYV"
STRAND 724..732
/evidence="ECO:0000244|PDB:1FYV"
HELIX 736..738
/evidence="ECO:0000244|PDB:1FYV"
HELIX 744..751
/evidence="ECO:0000244|PDB:1FYV"
HELIX 762..764
/evidence="ECO:0000244|PDB:1FYV"
HELIX 767..777
/evidence="ECO:0000244|PDB:1FYV"
SEQUENCE 786 AA; 90291 MW; 1BFCCC5E42EA5242 CRC64;
MTSIFHFAII FMLILQIRIQ LSEESEFLVD RSKNGLIHVP KDLSQKTTIL NISQNYISEL
WTSDILSLSK LRILIISHNR IQYLDISVFK FNQELEYLDL SHNKLVKISC HPTVNLKHLD
LSFNAFDALP ICKEFGNMSQ LKFLGLSTTH LEKSSVLPIA HLNISKVLLV LGETYGEKED
PEGLQDFNTE SLHIVFPTNK EFHFILDVSV KTVANLELSN IKCVLEDNKC SYFLSILAKL
QTNPKLSNLT LNNIETTWNS FIRILQLVWH TTVWYFSISN VKLQGQLDFR DFDYSGTSLK
ALSIHQVVSD VFGFPQSYIY EIFSNMNIKN FTVSGTRMVH MLCPSKISPF LHLDFSNNLL
TDTVFENCGH LTELETLILQ MNQLKELSKI AEMTTQMKSL QQLDISQNSV SYDEKKGDCS
WTKSLLSLNM SSNILTDTIF RCLPPRIKVL DLHSNKIKSI PKQVVKLEAL QELNVAFNSL
TDLPGCGSFS SLSVLIIDHN SVSHPSADFF QSCQKMRSIK AGDNPFQCTC ELGEFVKNID
QVSSEVLEGW PDSYKCDYPE SYRGTLLKDF HMSELSCNIT LLIVTIVATM LVLAVTVTSL
CSYLDLPWYL RMVCQWTQTR RRARNIPLEE LQRNLQFHAF ISYSGHDSFW VKNELLPNLE
KEGMQICLHE RNFVPGKSIV ENIITCIEKS YKSIFVLSPN FVQSEWCHYE LYFAHHNLFH
EGSNSLILIL LEPIPQYSIP SSYHKLKSLM ARRTYLEWPK EKSKRGLFWA NLRAAINIKL
TEQAKK


Related products :

Catalog number Product name Quantity
20-321-175164 TOLL-LIKE RECEPTOR 1 (TLR1. CD281) - FITC CONJUGATED MONOCLONAL ANTIBODY TO HUMAN TOLL-LIKE RECEPTOR 1 (TLR1. CD281); Toll_interleukin-1 receptor-like protein; TIL; CD281 antigen Monoclonal 0.1 mg
20-321-175165 TOLL-LIKE RECEPTOR 1 (TLR1. CD281) - BIOTINYLATED MONOCLONAL ANTIBODY TO HUMAN TOLL-LIKE RECEPTOR 1 (TLR1. CD281); Toll_interleukin-1 receptor-like protein; TIL; CD281 antigen Monoclonal 0.05 mg
20-321-175163 TOLL-LIKE RECEPTOR 1 (TLR1. CD281) - MONOCLONAL ANTIBODY TO HUMAN TOLL-LIKE RECEPTOR 1 (TLR1. CD281); Toll_interleukin-1 receptor-like protein; TIL; CD281 antigen Monoclonal 0.1 mg
LF-PA41656 anti-Toll-interleukin 1 Receptor, Rabbit polyclonal to Toll-interleukin 1 Receptor, Isotype IgG, Host Rabbit 100 ul
20-321-175147 TOLL-LIKE RECEPTOR 2 (TLR2. CD282) - FITC CONJUGATED MONOCLONAL ANTIBODY TO HUMAN TOLL-LIKE RECEPTOR 2 (TLR2. CD282); Toll_interleukin 1 receptor-like protein 4; CD282 antigen Monoclonal 0.1 mg
20-321-175144 TOLL-LIKE RECEPTOR 2 (TLR2. CD282) - FITC CONJUGATED MONOCLONAL ANTIBODY TO HUMAN TOLL-LIKE RECEPTOR 2 (TLR2. CD282); Toll_interleukin 1 receptor-like protein 4; CD282 antigen Monoclonal 0.1 mg
20-321-175148 TOLL-LIKE RECEPTOR 2 (TLR2. CD282) - BIOTINYLATED MONOCLONAL ANTIBODY TO HUMAN TOLL-LIKE RECEPTOR 2 (TLR2. CD282); Toll_interleukin 1 receptor-like protein 4; CD282 antigen Monoclonal 0.05 mg
20-321-175145 TOLL-LIKE RECEPTOR 2 (TLR2. CD282) - BIOTINYLATED MONOCLONAL ANTIBODY TO HUMAN TOLL-LIKE RECEPTOR 2 (TLR2. CD282); Toll_interleukin 1 receptor-like protein 4; CD282 antigen Monoclonal 0.05 mg
20-321-175146 TOLL-LIKE RECEPTOR 2 (TLR2. CD282) - MONOCLONAL ANTIBODY TO HUMAN TOLL-LIKE RECEPTOR 2 (TLR2. CD282); Toll_interleukin 1 receptor-like protein 4; CD282 antigen Monoclonal 0.1 mg
20-321-175143 TOLL-LIKE RECEPTOR 2 (TLR2. CD282) - MONOCLONAL ANTIBODY TO HUMAN TOLL-LIKE RECEPTOR 2 (TLR2. CD282); Toll_interleukin 1 receptor-like protein 4; CD282 antigen Monoclonal 0.1 mg
GWB-BDA142 TOLL-LIKE RECEPTOR 1 (TLR1. CD281), Antibody
GWB-CCB3EA TOLL-LIKE RECEPTOR 1 (TLR1. CD281), Antibody
GWB-EA7878 TOLL-LIKE RECEPTOR 1 (TLR1. CD281), Antibody
18-661-15147 Toll-like receptor 2 - Toll_interleukin 1 receptor-like protein 4; CD282 antigen Polyclonal 0.1 mg
15-288-22787 Toll-like receptor 2 - Toll_interleukin 1 receptor-like protein 4; CD282 antigen Polyclonal 0.1 mg
15-288-22787 Toll-like receptor 2 - Toll_interleukin 1 receptor-like protein 4; CD282 antigen Polyclonal 0.05 mg
LF-MA41374 anti-Toll-like Receptor 4 (76B357.1) , Mouse monoclonal to Toll-like Receptor 4, Isotype IgG2b, Host Mouse 50 ug
LF-MA41451 anti-Toll-like Receptor 4 (5K155) , Mouse monoclonal to Toll-like Receptor 4, Isotype IgG2a, Host Mouse 50 ug
20-321-175150 TOLL-LIKE RECEPTOR 4 (TLR4. CD284) - FITC CONJUGATED MONOCLONAL ANTIBODY TO HUMAN TOLL-LIKE RECEPTOR 4 (TLR4. CD284); Toll4; CD284 antigen Monoclonal 0.1 mg
LF-MA10344 anti-Toll-like Receptor 8 (4C6) , Mouse monoclonal to Toll-like Receptor 8, Isotype IgG2b, Host Mouse 100 ug
20-321-175151 TOLL-LIKE RECEPTOR 4 (TLR4. CD284) - BIOTINYLATED MONOCLONAL ANTIBODY TO HUMAN TOLL-LIKE RECEPTOR 4 (TLR4. CD284); Toll4; CD284 antigen Monoclonal 0.05 mg
RPR-181 Recombinant Human Toll-Interleukin 1 Receptor (TIR) Domain Containing Adaptor Protein 2
EH2296 Toll per interleukin-1 receptor domain-containing adapter protein Elisa Kit 96T
20-321-175172 TOLL-LIKE RECEPTOR 3 (TLR3. CD283) - BIOTINYLATED MONOCLONAL ANTIBODY TO HUMAN TOLL-LIKE RECEPTOR 3 (TLR3. CD283); CD283 antigen Monoclonal 0.05 mg
20-321-175167 TOLL-LIKE RECEPTOR 9 (TLR9. CD289) - BIOTINYLATED MONOCLONAL ANTIBODY TO HUMAN TOLL-LIKE RECEPTOR 9 (TLR9. CD289); CD289 antigen Monoclonal 0.05 mg
Pathways :
WP2272: Pathogenic Escherichia coli infection
WP1183: Toll-like receptor signaling pathway
WP829: Toll-like receptor signaling pathway
WP1309: Toll-like receptor signaling pathway
WP1384: Toll-like receptor signaling pathway
WP1449: Regulation of toll-like receptor signaling pathway
WP88: Toll Like Receptor signaling
WP949: Toll-like receptor signaling pathway
WP1271: Toll-like receptor signaling pathway
WP1067: Toll-like receptor signaling pathway
WP75: Toll-like receptor signaling pathway
WP2328: Allograft rejection
WP2292: Chemokine signaling pathway
WP780: T Cell Receptor Signaling Pathway
WP474: Endochondral Ossification
WP94: Signaling of Hepatocyte Growth Factor Receptor
WP1004: Kit Receptor Signaling Pathway
WP566: canonical wnt - zebrafish
WP1025: B Cell Receptor Signaling Pathway
WP147: Kit Receptor Signaling Pathway
WP252: Androgen Receptor Signaling Pathway
WP809: TGF-beta Receptor Signaling Pathway
WP1249: EPO Receptor Signaling
WP1869: Neuroransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
WP274: B Cell Receptor Signaling Pathway

Related Genes :
[Tlr1] Toll-like receptor 1 (EC 3.2.2.6) (Toll/interleukin-1 receptor-like protein) (TIL) (CD antigen CD281)
[TLR1 KIAA0012] Toll-like receptor 1 (EC 3.2.2.6) (Toll/interleukin-1 receptor-like protein) (TIL) (CD antigen CD281)
[TLR2 TIL4] Toll-like receptor 2 (EC 3.2.2.6) (Toll/interleukin-1 receptor-like protein 4) (CD antigen CD282)
[TLR5 TIL3] Toll-like receptor 5 (Toll/interleukin-1 receptor-like protein 3)
[TICAM2 TIRAP3 TIRP TRAM] TIR domain-containing adapter molecule 2 (TICAM-2) (Putative NF-kappa-B-activating protein 502) (TRIF-related adapter molecule) (Toll-like receptor adaptor protein 3) (Toll/interleukin-1 receptor domain-containing protein) (MyD88-4)
[Ceacam1 Bgp Bgp1] Carcinoembryonic antigen-related cell adhesion molecule 1 (Biliary glycoprotein 1) (BGP-1) (Biliary glycoprotein D) (MHVR1) (Murine hepatitis virus receptor) (MHV-R) (CD antigen CD66a)
[TICAM1 PRVTIRB TRIF] TIR domain-containing adapter molecule 1 (TICAM-1) (Proline-rich, vinculin and TIR domain-containing protein B) (Putative NF-kappa-B-activating protein 502H) (Toll-interleukin-1 receptor domain-containing adapter protein inducing interferon beta) (MyD88-3) (TIR domain-containing adapter protein inducing IFN-beta)
[TIRAP MAL] Toll/interleukin-1 receptor domain-containing adapter protein (TIR domain-containing adapter protein) (Adaptor protein Wyatt) (MyD88 adapter-like protein) (MyD88-2)
[Ticam1 Trif] TIR domain-containing adapter molecule 1 (TICAM-1) (Toll-interleukin-1 receptor domain-containing adapter protein inducing interferon beta) (TIR domain-containing adapter protein inducing IFN-beta)
[Tlr2] Toll-like receptor 2 (EC 3.2.2.6) (CD antigen CD282)
[Ticam2 Tirp Tram] TIR domain-containing adapter molecule 2 (TICAM-2) (TRIF-related adapter molecule) (Toll/interleukin-1 receptor domain-containing protein)
[IL1R1 IL1R IL1RA IL1RT1] Interleukin-1 receptor type 1 (IL-1R-1) (IL-1RT-1) (IL-1RT1) (EC 3.2.2.6) (CD121 antigen-like family member A) (Interleukin-1 receptor alpha) (IL-1R-alpha) (Interleukin-1 receptor type I) (p80) (CD antigen CD121a) [Cleaved into: Interleukin-1 receptor type 1, membrane form (mIL-1R1) (mIL-1RI); Interleukin-1 receptor type 1, soluble form (sIL-1R1) (sIL-1RI)]
[IL18RAP IL1R7] Interleukin-18 receptor accessory protein (IL-18 receptor accessory protein) (IL-18RAcP) (EC 3.2.2.6) (Accessory protein-like) (AcPL) (CD218 antigen-like family member B) (CDw218b) (IL-1R accessory protein-like) (IL-1RAcPL) (Interleukin-1 receptor 7) (IL-1R-7) (IL-1R7) (Interleukin-18 receptor accessory protein-like) (Interleukin-18 receptor beta) (IL-18R-beta) (IL-18Rbeta) (CD antigen CD218b)
[Il1r1 Il-1r1 Il1ra] Interleukin-1 receptor type 1 (IL-1R-1) (IL-1RT-1) (IL-1RT1) (EC 3.2.2.6) (CD121 antigen-like family member A) (Interleukin-1 receptor alpha) (IL-1R-alpha) (Interleukin-1 receptor type I) (p80) (CD antigen CD121a) [Cleaved into: Interleukin-1 receptor type 1, membrane form (mIL-1R1) (mIL-1RI); Interleukin-1 receptor type 1, soluble form (sIL-1R1) (sIL-1RI)]
[TLR4] Toll-like receptor 4 (EC 3.2.2.6) (hToll) (CD antigen CD284)
[Il1r1 Il1ra] Interleukin-1 receptor type 1 (IL-1R-1) (IL-1RT-1) (IL-1RT1) (EC 3.2.2.6) (CD121 antigen-like family member A) (Interleukin-1 receptor alpha) (IL-1R-alpha) (Interleukin-1 receptor type I) (p80) (CD antigen CD121a) [Cleaved into: Interleukin-1 receptor type 1, membrane form (mIL-1R1) (mIL-1RI); Interleukin-1 receptor type 1, soluble form (sIL-1R1) (sIL-1RI)]
[Tlr4] Toll-like receptor 4 (Toll4) (EC 3.2.2.6) (CD antigen CD284)
[IL18R1 IL1RRP] Interleukin-18 receptor 1 (IL-18R-1) (IL-18R1) (EC 3.2.2.6) (CD218 antigen-like family member A) (CDw218a) (IL1 receptor-related protein) (IL-1Rrp) (IL1R-rp) (Interleukin-18 receptor alpha) (IL-18R-alpha) (IL-18Ralpha) (CD antigen CD218a)
[Il18r1] Interleukin-18 receptor 1 (IL-18R-1) (IL-18R1) (EC 3.2.2.6) (CD218 antigen-like family member A) (IL1 receptor-related protein) (IL-1Rrp) (IL1R-rp) (Interleukin-18 receptor alpha) (IL-18R-alpha) (IL-18Ralpha) (CD antigen CD218a)
[TLR6] Toll-like receptor 6 (EC 3.2.2.6) (CD antigen CD286)
[TLR4] Toll-like receptor 4 (EC 3.2.2.6) (CD antigen CD284)
[Sigirr Tir8] Single Ig IL-1-related receptor (Single Ig IL-1R-related molecule) (Single immunoglobulin domain-containing IL1R-related protein) (Toll/interleukin-1 receptor 8) (TIR8)
[Tlr4 Lps] Toll-like receptor 4 (EC 3.2.2.6) (CD antigen CD284)
[Tlr9] Toll-like receptor 9 (CD antigen CD289)
[TLR9 UNQ5798/PRO19605] Toll-like receptor 9 (CD antigen CD289)
[Tlr6] Toll-like receptor 6 (EC 3.2.2.6) (CD antigen CD286)
[TLR6] Toll-like receptor 6 (EC 3.2.2.6) (CD antigen CD286)
[TLR4] Toll-like receptor 4 (EC 3.2.2.6) (CD antigen CD284)
[TLR2] Toll-like receptor 2 (EC 3.2.2.6) (CD antigen CD282)
[TLR2] Toll-like receptor 2 (EC 3.2.2.6) (CD antigen CD282)

Bibliography :
No related Items